Diagnostic value of cyclin-dependent kinase/cyclin-dependent kinase inhibitor expression ratios as biomarkers of locoregional and hematogenous dissemination risks in oral squamous cell carcinoma

Nakagawa, Masaki; Kitamura, Hiroshi; Uematsu, Kohya; Ogawa, Shin; Takahashi, Kazuyuki; Hoshina, Hideyuki; Takagi, Ritsuo

doi:10.3892/mco.2015.578

Cited by 16 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was mainly expressed in the stratum basal, co-localizing with the region that contained stem cells. 14 SOX2 activity was organized by several microRNAs, thus particular microRNAs might be controlled by SOX2, such as microRNA-145 15 and microRNA-302. 16 Also, it has a role in oncogenesis in OSCC by driving the epithelialmesenchymal transition (EMT) an important factor in metastasis.…”

Section: Discussionmentioning

confidence: 99%

SOX2 expression inversely correlates with histological grading, nodal metastasis and clinical staging of Oral Squamous Cell Carcinoma

Elmogy¹,

Gaballah²,

Farag³

et al. 2020

JDPO

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) accounts for 95% of entire oral malignant tumors. The development as well as the distribution of many tumors such as OSCC is driven by cancer stem cells (CSCs). Sex determining region Y-box 2 (SOX2) is a functional CSCs marker; it is a transcription factor coding gene, present at chromosomal 3q26.33 area. The current study was conducted to evaluate SOX2 immunohistochemical expression in OSCC in addition to correlation of its expression in various histologic grades and the existing clinical parameters. Paraffin blocks tumor tissues from forty patients of OSCC were utilized to assess SOX2 immunohistochemical expression. The present study demonstrated that SOX2 expression displayed highly significant inverse association with histologic differentiation of OSCC (P=0.001), clinical stages (P=0.007) and lymph node metastases (LNM) (P=0.035). The current study recommended that, SOX2 expression might be utilized as a prognostic predictor for OSCC, and might help in establishment of the diagnosis as well as proper selection of therapeutic modality of cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

SOX2 expression inversely correlates with histological grading, nodal metastasis and clinical staging of Oral Squamous Cell Carcinoma

Elmogy¹,

Gaballah²,

Farag³

et al. 2020

JDPO

View full text Add to dashboard Cite

show abstract

“…The junction plakoglobin gene (JUP) is a desmosomal anchor protein gene, whose normal functioning is necessary for having healthy inter-cellular junctions and microtubules [30–31]. JUP is abnormally expressed in various diseases, including cancer (Table 4) [30–33], and its overexpression promotes metastasis and primary site recurrence in squamous cell carcinoma [34–35]; thus, JUP levels might also inform on the recurrence of FPA.…”

Section: Discussionmentioning

confidence: 99%

T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma

Zhong

et al. 2019

Aging

View full text Add to dashboard Cite

We tested whether the drugs T5224, RSPO2, and AZD5363 exert therapeutic effects against functioning pituitary adenoma (FPA). We analysed the gene expression profiles of four FPA mRNA microarray datasets (GSE2175, GSE26966, GSE36314, and GSE37153) from the Gene Expression Omnibus database and identified genes differentially expressed in FPA vs control tissues. We then carried out Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction network analyses. We also measured the difference in expression of hub genes between human normal pituitary cells and FPA cells using qRT-PCR. Our in vitro colony-formation and MTT assays showed that cell viability, number, and the size of clonogenicities were all lower in the presence of T5224, RSPO2, or AZD536 than in controls. Moreover, flow cytometry experiments showed that the incidence of apoptosis was higher in the presence of T5224, RSPO2, or AZD5363 than among controls, and was increased by increasing the doses of the drugs. This suggests these drugs could be used as therapeutic agents to treat FPA. Finally, we found that cFos, WNT5A, NCAM1, JUP, AKT3, and ADCY1 are abnormally expressed in FPA cells compared to controls, which highlights these genes as potential prognostic and/or therapeutic targets.

show abstract

“…Deregulation of the cell cycle is a common characteristic of human cancer while cell-cycle regulatory proteins are critical determinants of malignancy progression. Genes controlling G1, S, G2 and M phases of the cell cycle - including cyclin-dependent kinases (CDKs), cyclins activating CDKs and cyclin-dependent kinase inhibitors (CDKIs) - are crucial for the control of mammalian cell proliferation [38, 39].…”

Section: Discussionmentioning

confidence: 99%

BjussuLAAO-II induces cytotoxicity and alters DNA methylation of cell-cycle genes in monocultured/co-cultured HepG2 cells

Machado

Aissa

Ribeiro

et al. 2019

J. Venom. Anim. Toxins incl. Trop. Dis

View full text Add to dashboard Cite

Background: The use of animal venoms and their toxins as material sources for biotechnological applications has received much attention from the pharmaceutical industry. L-amino acid oxidases from snake venoms (SV-LAAOs) have demonstrated innumerous biological effects and pharmacological potential against different cancer types. Hepatocellular carcinoma has increased worldwide, and the aberrant DNA methylation of liver cells is a common mechanism to promote hepatic tumorigenesis. Moreover, tumor microenvironment plays a major role in neoplastic transformation. To elucidate the molecular mechanisms responsible for the cytotoxic effects of SV-LAAO in human cancer cells, this study aimed to evaluate the cytotoxicity and the alterations in DNA methylation profiler in the promoter regions of cell-cycle genes induced by BjussuLAAO-II, an LAAO from Bothrops jaracussu venom, in human hepatocellular carcinoma (HepG2) cells in monoculture and co-culture with endothelial (HUVEC) cells. Methods: BjussuLAAO-II concentrations were 0.25, 0.50, 1.00 and 5.00 μg/mL. Cell viability was assessed by MTT assay and DNA methylation of the promoter regions of 22 cell-cycle genes by EpiTect Methyl II PCR array. Results: BjussuLAAO-II decreased the cell viability of HepG2 cells in monoculture at all concentrations tested. In co-culture, 1.00 and 5.00 μg/mL induced cytotoxicity ( p < 0.05). BjussuLAAO-II increased the methylation of CCND1 and decreased the methylation of CDKN1A in monoculture and GADD45A in both cell-culture models ( p < 0.05). Conclusion: Data showed BjussuLAAO-II induced cytotoxicity and altered DNA methylation of the promoter regions of cell-cycle genes in HepG2 cells in monoculture and co-culture models. We suggested the analysis of DNA methylation profile of GADD45A as a potential biomarker of the cell cycle effects of BjussuLAAO-II in cancer cells. The tumor microenvironment should be considered to comprise part of biotechnological strategies during the development of snake-toxin-based novel drugs.

show abstract

Diagnostic value of cyclin-dependent kinase/cyclin-dependent kinase inhibitor expression ratios as biomarkers of locoregional and hematogenous dissemination risks in oral squamous cell carcinoma

Cited by 16 publications

References 16 publications

SOX2 expression inversely correlates with histological grading, nodal metastasis and clinical staging of Oral Squamous Cell Carcinoma

SOX2 expression inversely correlates with histological grading, nodal metastasis and clinical staging of Oral Squamous Cell Carcinoma

T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma

BjussuLAAO-II induces cytotoxicity and alters DNA methylation of cell-cycle genes in monocultured/co-cultured HepG2 cells

Contact Info

Product

Resources

About